Beranda › Kanker Serviks › Illinois
Uji klinis Kanker Serviks di Illinois
15 studi untuk Kanker Serviks mencari peserta di lokasi di Illinois.
Kota di Illinois
Teks studi resmi (Bahasa Inggris)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Chicago Hospital, Chicago
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06465069A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- University of Illinois Cancer Center, Chicago
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06172478Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- University of Chicago, Chicago
Menerima pesertaStudi observasional
Usia 18 ke atas · Wanita · Diperbarui 29 Sep 2026 · NCT05051722DESTINY-PANTUMOUR04
- Research Site, Decatur
Menerima pesertaStudi observasional
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07124000Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
- Rush University Medical Center, Chicago
- Rush University Medical Center, Ophthalmology, Chicago
- Illinois Eye Center, Peoria
- dan 1 lainnya
Menerima pesertaFase 4
Usia 18 ke atas · Wanita · Diperbarui 25 Sep 2026 · NCT06952660Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Northwestern University Feinberg School of Medicine, Chicago
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT05983432A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- City of Hope, Chicago, Zion
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07109726Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
- City of Hope - Chicago, Zion
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT06293898A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Orchard Healthcare Research Inc, Skokie
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT06330064A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Ingalls Family Care Center, Calumet City
- UChicago Medicine - River East, Chicago
- The University Of Chicago, Chicago
- dan 13 lainnya
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT04389632Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
- Northwestern University, Chicago
Menerima peserta
Usia 60 ke atas · Wanita · Diperbarui 29 Mei 2026 · NCT05743517Detecting HPV DNA in Anal and Cervical Cancers
- University of Illinois at Chicago, Chicago
- University of Chicago, Chicago
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Mar 2026 · NCT04857528SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chicago
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774A Study of NX-1607 in Adults With Advanced Malignancies
- University of Chicago, Chicago
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2025 · NCT05107674Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 hingga 80 · Wanita · Diperbarui 28 Feb 2025 · NCT00005095Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.